Endo International Ordinary Shares traded at $0.0001 this Tuesday April 9th, decreasing $0.0003 or 75.00 percent since the previous trading session. Looking back, over the last four weeks, Endo International lost 90.91 percent. Over the last 12 months, its price fell by 99.86 percent. Looking ahead, we forecast Endo International Ordinary Shares to be priced at 0.0001 by the end of this quarter and at 0.0001 in one year, according to Trading Economics global macro models projections and analysts expectations.
Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.